免疫学领域的合作与授权协议（2016-2025）

本报告以前所未有的方式，全面深入地展现了全球领先的生物製药公司签署的免疫学相关合作与许可协议。

本报告详细介绍了2016年至2025年间909项免疫学相关交易。

本报告提供了各方已公布交易的付款条款。这些数据有助于深入了解付款条款和其他交易条款。

了解潜在合作伙伴协商的交易条款的弹性，有助于深入了解谈判过程，从而预估谈判的预期成果。虽然许多中小企业会寻求详细的付款条款，但魔鬼藏在细节里，尤其是在付款方式和权利转让方面。

本报告全面列出了自 2016 年以来在 "当前协议交易与联盟" 资料库中记录的所有合作与许可协议，包括财务条款（如有）以及公司及其合作伙伴向美国证券交易委员会 (SEC) 提交的实际许可协议的线上副本连结。

本报告第一章探讨了免疫学领域的交易和商业活动。第一章为报告的引言，第二章分析了免疫学领域的交易趋势。

第三章介绍了免疫学领域已完成交易的财务条款和发展阶段。交易按总价值、首付款、里程碑付款和特许权使用费率进行分类。

第四章回顾了在免疫学交易中最活跃的 25 家生物製药公司。对于已向 SEC 公开披露的协议，可透过 "当前协议交易与联盟" 资料库线上存取。

第五章对2016年以来已完成和已宣布的免疫学交易进行了全面深入的回顾，这些交易均有相关文件可供查阅。每项交易标题都提供了一个指向在线交易文件的链接，方便读者随时查阅。

第六章提供了一个按目标公司分类的免疫学交易综合目录。

本书也包含大量图表，展示了自2016年以来免疫学交易的趋势和活动。

此外，此综合交易目录按公司名称（A-Z）和技术类型进行分类。每项交易标题都提供了一个指向在线交易记录的链接，并在可用的情况下提供协议文件，方便读者随时查阅。

主要优势

"免疫学领域的合作与授权协议" 提供读者以下主要优势：

• 了解自 2016 年以来的交易趋势
• 浏览免疫学领域的合作与授权交易
• 基准分析 - 确定交易的市场价值
• 财务条款 - 预付款、里程碑付款、特许权使用费
• 按公司 A-Z、治疗领域和技术类型分类的交易目录
• 主要交易金额
• 最活跃的交易撮合者
• 确定每笔交易的资产和交易条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款是否适合您的合作伙伴
• 节省数百小时的研究时间

范围

• 免疫学领域的合作与授权协议 "授权协议报告" 旨在帮助全球领先的生物製药公司深入了解免疫学领域的趋势和交易结构。

免疫学合作与授权协议包括：

• 生物製药产业免疫学相关交易趋势
• 合作与授权协议架构概述
• 涵盖製药和生物技术的免疫学交易记录目录
• 主要免疫学交易
• 最活跃的免疫学许可公司

以下列出了可用的免疫学合作与授权交易。

• 公司 A-Z
• 主要交易金额
• 治疗领域
• 技术类型
• 每个交易标题都透过网路连结指向实际的线上交易记录，方便您轻鬆存取每份协议文件。
• 免疫学领域的合作与授权协议提供对交易记录（包括协议文件）的全面存取。

对这些协议的分析有助于进行尽职调查，包括：

• 具体授予或选择哪些权利？
• 根据合同，合作伙伴实际获得哪些权益？
• 授予了哪些排他性权利？
• 合约的付款结构是什么？
• 如何对销售和付款进行审计？
• 合约期限是多久？
• 如何定义合约的关键条款？
• 如何处理并拥有知识产权？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和资讯揭露？
• 如何解决争议？
• 在什么情况下可以终止合约？
• 如果所有权发生变更，会发生什么事？
• 已达成哪些转许可或分包条款？
• 公司坚持哪些标准条款？
• 哪些标准条款似乎因合作伙伴和交易类型而异？
• 公司主张其在契约法方面享有哪一个管辖权？

目录

摘要整理

第一章：引言

第二章：免疫学交易趋势

• 引言
• 长期免疫学合作
• 按交易类型划分的免疫学合作
• 按行业划分的免疫学合作
• 依研发阶段划分的免疫学合作
• 按技术类型划分的免疫学合作
• 按治疗适应症划分的免疫学合作

第三章：免疫学合作的财务条款

• 引言
• 揭露免疫学合作的财务条款
• 关键价值策略免疫学合作
• 免疫学交易中的预付款
• 免疫学交易中的里程碑付款
• 免疫学特许权使用费率

第四章：重要的免疫学交易与交易撮合者

• 引言
• 最活跃的免疫学合作者
• 最活跃的免疫学交易撮合者名单
• 以价值为排名的顶级免疫学交易

第五章：免疫学合约文件目录

• 引言
• 可提供合约的免疫学合作协议

第六章：依治疗标靶分类的免疫学交易

• 引言
• 以免疫疗法标靶分类的交易
• 交易目录
• 交易目录 -免疫学领域交易（按公司、亚利桑那州、2016-2025 年）
• 交易目录 - 免疫学领域交易（依技术类型、2016-2025 年）
• 交易类型定义
• 关于研究公司
• 当前合作关係
• 当前协议
• 近期当前合作关係报告标题

Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 909 immunology deals from 2016 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of immunology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in immunology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the immunology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in immunology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of immunology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of immunology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in immunology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Immunology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse immunology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Immunology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of immunology trends and structure of deals entered into by leading biopharma companies worldwide.

Immunology Collaboration and Licensing Deals includes:

• Trends in immunology dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of immunology deal records covering pharmaceutical and biotechnology
• The leading immunology deals by value
• Most active immunology licensing dealmakers

In Immunology Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Immunology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in immunology dealmaking

• 2.1. Introduction
• 2.2. Immunology partnering over the years
• 2.3. Immunology partnering by deal type
• 2.4. Immunology partnering by industry sector
• 2.5. Immunology partnering by stage of development
• 2.6. Immunology partnering by technology type
• 2.7. Immunology partnering by therapeutic indication

Chapter 3 - Financial deal terms for immunology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for immunology partnering
• 3.3. Immunology partnering headline values
• 3.4. Immunology deal upfront payments
• 3.5. Immunology deal milestone payments
• 3.6. Immunology royalty rates

Chapter 4 - Leading immunology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in immunology partnering
• 4.3. List of most active dealmakers in immunology
• 4.4. Top immunology deals by value

Chapter 5 - Immunology contract document directory

• 5.1. Introduction
• 5.2. Immunology partnering deals where contract document available

Chapter 6 - Immunology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by immunology therapeutic target
• Deal directory
• Deal directory - Immunology deals by company A-Z 2016 to 2025
• Deal directory - Immunology deals by technology type 2016 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Immunology partnering since 2016
• Figure 2: Immunology partnering by deal type since 2016
• Figure 3: Immunology partnering by industry sector since 2016
• Figure 4: Immunology partnering by stage of development since 2016
• Figure 5: Immunology partnering by technology type since 2016
• Figure 6: Immunology partnering by indication since 2016
• Figure 7: Immunology deals with a headline value
• Figure 8: Immunology deals with upfront payment values
• Figure 9: Immunology deals with milestone payment
• Figure 10: Immunology deals with royalty rates
• Figure 11: Active immunology dealmaking activity since 2016
• Figure 12: Top immunology deals by value since 2016